| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1023615563 |
| P356 | DOI | 10.1007/S00125-005-1682-X |
| P698 | PubMed publication ID | 15747110 |
| P5875 | ResearchGate publication ID | 7987291 |
| P50 | author | Amalia Gastaldelli | Q43294287 |
| Eleuterio Ferrannini | Q59193801 | ||
| P2093 | author name string | M Rizzetto | |
| G Pagano | |||
| M Cassader | |||
| R Gambino | |||
| E Bugianesi | |||
| S Baldi | |||
| V Ponti | |||
| E Vanni | |||
| P2860 | cites work | Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) | Q27860959 |
| Nonalcoholic fatty liver disease: a feature of the metabolic syndrome | Q28208772 | ||
| Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease | Q28282463 | ||
| Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression | Q28367828 | ||
| Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus | Q29616284 | ||
| Mechanisms underlying regional differences in lipolysis in human adipose tissue | Q33847938 | ||
| Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein? | Q34010660 | ||
| Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study | Q34044074 | ||
| Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association | Q34112671 | ||
| Glucose clamp technique: a method for quantifying insulin secretion and resistance | Q34191986 | ||
| Effect of physiologic hyperinsulinemia on glucose and lipid metabolism in cirrhosis | Q34193422 | ||
| Clinical features and natural history of nonalcoholic steatosis syndromes | Q34215131 | ||
| Nonalcoholic steatohepatitis: definition and pathology | Q34215155 | ||
| Resistin, obesity, and insulin resistance--the emerging role of the adipocyte as an endocrine organ | Q34495976 | ||
| Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. | Q34525065 | ||
| Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance | Q34577169 | ||
| Mechanism of insulin resistance in human liver cirrhosis. Evidence of a combined receptor and postreceptor defect | Q34628137 | ||
| Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease | Q35904142 | ||
| Lipid advanced glycosylation: pathway for lipid oxidation in vivo | Q36412583 | ||
| Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease | Q37742798 | ||
| Nonalcoholic steatohepatitis: a study of 49 patients | Q38632482 | ||
| The theoretical bases of indirect calorimetry: a review | Q39629809 | ||
| Abdominal obesity as important component of insulin-resistance syndrome | Q40803600 | ||
| The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus | Q41176971 | ||
| Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors | Q41208203 | ||
| Stimulation of collagen alpha 1(I) gene expression is associated with lipid peroxidation in hepatocellular injury: a link to tissue fibrosis? | Q42285597 | ||
| Glucose turnover and adipose tissue lipolysis are insulin-resistant in healthy relatives of type 2 diabetes patients: is cellular insulin resistance a secondary phenomenon? | Q42475544 | ||
| Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis | Q42498476 | ||
| Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities | Q43552270 | ||
| Sources of blood glycerol during fasting | Q43762948 | ||
| Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes | Q43833528 | ||
| NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome | Q43875846 | ||
| Apolipoprotein synthesis in nonalcoholic steatohepatitis | Q43933950 | ||
| Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. | Q44055110 | ||
| Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States | Q44269254 | ||
| Prevalence of fatty liver in a general population of Okinawa, Japan | Q44378144 | ||
| Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome | Q44385945 | ||
| The prevalence and etiology of elevated aminotransferase levels in the United States | Q44480010 | ||
| Metabolic and anthropometric evaluation of insulin resistance in nondiabetic patients with nonalcoholic steatohepatitis | Q44542170 | ||
| Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance | Q44575979 | ||
| Visceral fat in hypertension: influence on insulin resistance and beta-cell function | Q44985642 | ||
| Measurement of abdominal fat with T1-weighted MR images | Q45076799 | ||
| Determinants of postabsorptive endogenous glucose output in non-diabetic subjects. European Group for the Study of Insulin Resistance (EGIR). | Q51552659 | ||
| Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. | Q51554896 | ||
| Association of nonalcoholic fatty liver disease with insulin resistance. | Q51559831 | ||
| Regional glycerol and free fatty acid metabolism before and after meal ingestion. | Q51563532 | ||
| Basal hepatic glucose production is regulated by the portal vein insulin concentration. | Q51570329 | ||
| Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. | Q51621447 | ||
| Non-steady state: error analysis of Steele's model and developments for glucose kinetics. | Q52428176 | ||
| Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients. | Q54150642 | ||
| Fat metabolism during high-intensity exercise in endurance-trained and untrained men | Q60462236 | ||
| Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group | Q66972631 | ||
| Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates | Q68161753 | ||
| Continuous monitoring of in vitro oxidation of human low density lipoprotein | Q69611707 | ||
| Prevalence of and risk factors for hepatic steatosis in Northern Italy | Q73375973 | ||
| Depot-specific differences in adipose tissue gene expression in lean and obese subjects | Q74013169 | ||
| Identification of oxidized low-density lipoprotein in human serum by NMR spectroscopy | Q77333391 | ||
| Quantification of gluconeogenesis in cirrhosis: response to glucagon | Q77620744 | ||
| P433 | issue | 4 | |
| P921 | main subject | metabolic dysfunction–associated steatotic liver disease | Q1546498 |
| preproinsulin | Q7240673 | ||
| patient | Q181600 | ||
| liver disease | Q929737 | ||
| insulin resistance | Q1053470 | ||
| non-alcoholic fatty liver | Q66299798 | ||
| P304 | page(s) | 634-642 | |
| P577 | publication date | 2005-03-04 | |
| P1433 | published in | Diabetologia | Q5270140 |
| P1476 | title | Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms | |
| P478 | volume | 48 |
| Q36134426 | A Computational Model of Hepatic Energy Metabolism: Understanding Zonated Damage and Steatosis in NAFLD |
| Q38230947 | A Review of the Effect of Dietary Composition on Fasting Substrate Oxidation in Healthy and Overweight Subjects. |
| Q51468646 | A comparison of associations of alanine aminotransferase and gamma-glutamyltransferase with fasting glucose, fasting insulin, and glycated hemoglobin in women with and without diabetes. |
| Q37359021 | A maternal high-fat diet is accompanied by alterations in the fetal primate metabolome |
| Q55332043 | A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis. |
| Q46307876 | A role for atorvastatin and insulin combination in protecting from liver injury in a model of type 2 diabetes with hyperlipidemia. |
| Q42379258 | A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease |
| Q34310464 | Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis |
| Q81235688 | Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance |
| Q36513125 | Adipose-specific disruption of signal transducer and activator of transcription 3 increases body weight and adiposity |
| Q37383372 | Alcohol consumption and risk of fatty liver disease: a meta-analysis |
| Q37250895 | Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. |
| Q37113695 | Alterations in fatty acid kinetics in obese adolescents with increased intrahepatic triglyceride content |
| Q38287516 | Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance |
| Q44557222 | Apolipoprotein B/AI ratio is independently associated with non-alcoholic fatty liver disease in nondiabetic subjects |
| Q54599587 | Apoptosis and insulin resistance in liver and peripheral tissues of morbidly obese patients is associated with different stages of non-alcoholic fatty liver disease. |
| Q34864638 | Are women with polycystic ovarian syndrome at a high risk of non-alcoholic Fatty liver disease; a meta-analysis |
| Q51246392 | Association Between Vitamin D Insufficiency and Metabolic Syndrome in Patients With Psychotic Disorders. |
| Q37264746 | Association between Serum Albumin, Insulin Resistance, and Incident Diabetes in Nondiabetic Subjects |
| Q37454017 | Association between metabolic syndrome and liver histology among NAFLD patients without diabetes |
| Q58588579 | Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis |
| Q37007637 | Atherosclerosis and Liver Function Tests in Coronary Angiography Patients |
| Q30377409 | Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. |
| Q91780954 | Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease |
| Q36449592 | Bisphenol A and Metabolic Syndrome: Results from NHANES. |
| Q38974667 | Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe. |
| Q55462318 | Characteristics of hepatic insulin-sensitive nonalcoholic fatty liver disease. |
| Q35912231 | Characteristics of nonalcoholic fatty liver disease induced in wistar rats following four different diets |
| Q92988472 | Chemical Effect of Bisphenol A on Non-Alcoholic Fatty Liver Disease |
| Q34449244 | Chronic enrichment of hepatic endoplasmic reticulum-mitochondria contact leads to mitochondrial dysfunction in obesity |
| Q39508242 | Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study |
| Q37095101 | Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: Do they differ from obese or overweight non-alcoholic fatty liver disease? |
| Q44598904 | Clostridium butyricum MIYAIRI 588 improves high-fat diet-induced non-alcoholic fatty liver disease in rats. |
| Q28478084 | Coordinated defects in hepatic long chain fatty acid metabolism and triglyceride accumulation contribute to insulin resistance in non-human primates |
| Q88794981 | Diagnostic performance of magnetic resonance technology in detecting steatosis or fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis |
| Q37299376 | Dietary anthocyanins as nutritional therapy for nonalcoholic fatty liver disease |
| Q49810183 | Dietary fat stimulates development of NAFLD more potently than dietary fructose in Sprague-Dawley rats |
| Q47367132 | Dietary α-lactalbumin induced fatty liver by enhancing nuclear liver X receptor αβ/sterol regulatory element-binding protein-1c/PPARγ expression and minimising PPARα/carnitine palmitoyltransferase-1 expression and AMP-activated protein kinase α phos |
| Q33987896 | Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia |
| Q37629154 | Dissociation of hepatic insulin resistance from susceptibility of nonalcoholic fatty liver disease induced by a high-fat and high-carbohydrate diet in mice. |
| Q46835749 | Downregulation of hepatic glucose-6-phosphatase-α in patients with hepatic steatosis |
| Q34957338 | Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice |
| Q35029623 | Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment |
| Q34460590 | E4orf1 improves lipid and glucose metabolism in hepatocytes: a template to improve steatosis & hyperglycemia |
| Q35126355 | Ectopic fat accumulation and distant organ-specific insulin resistance in Japanese people with nonalcoholic fatty liver disease |
| Q37107300 | Ectopic fat and adipokines in metabolically benign overweight/obese women: the Kronos Early Estrogen Prevention Study |
| Q21285128 | Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions |
| Q35864410 | Effect of Global ATGL Knockout on Murine Fasting Glucose Kinetics |
| Q90371069 | Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease |
| Q60462153 | Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease |
| Q33984899 | Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease |
| Q61810734 | Effects of AM80 compared to AC261066 in a high fat diet mouse model of liver disease |
| Q34295395 | Effects of acute glucocorticoid blockade on metabolic dysfunction in patients with Type 2 diabetes with and without fatty liver |
| Q64944611 | Effects of daphnetin on lipid metabolism, insulin resistance and oxidative stress in OA‑treated HepG2 cells. |
| Q61452212 | Effects of liver function, insulin resistance and inflammatory factors on vascular endothelial dilation function and prognosis of coronary heart disease patients complicated with NAFLD |
| Q36383494 | Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis |
| Q51970541 | Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. |
| Q39655248 | Evaluating -238 G>A Polymorphism Association in TNF-α Gene with Metabolic Parameters and Nutritional Intakes Among the Iranian NAFLD Patients |
| Q58573349 | Exercise Training Remodels Human Skeletal Muscle Mitochondrial Fission and Fusion Machinery Towards a Pro-Elongation Phenotype |
| Q99728028 | FIB-4 index is a marker for a subsequent decrease in insulin secretion in a non-diabetic Japanese population |
| Q64056545 | Fasting Whole-Body Energy Homeostasis and Hepatic Energy Metabolism in Nondiabetic Humans with Fatty Liver |
| Q26996360 | Fatty liver disease in diabetes mellitus |
| Q50992764 | Fatty liver disease, glucose tolerance and insulin resistance in obese adolescents. |
| Q34185998 | Fatty liver index predicts further metabolic deteriorations in women with previous gestational diabetes |
| Q89624033 | From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options |
| Q93164515 | From White to Brown - Adipose Tissue Is Critical to the Extended Lifespan and Healthspan of Growth Hormone Mutant Mice |
| Q42368231 | Fructose Consumption, Lipogenesis, and Non-Alcoholic Fatty Liver Disease. |
| Q35841726 | Gender Specific Association of Serum Leptin and Insulinemic Indices with Nonalcoholic Fatty Liver Disease in Prediabetic Subjects |
| Q38292078 | Gene expression in human NAFLD. |
| Q26798151 | Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis |
| Q37362755 | Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. |
| Q38389889 | Ghrelin-ghrelin O-acyltransferase system in the pathogenesis of nonalcoholic fatty liver disease |
| Q45067817 | Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention |
| Q97682178 | Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review |
| Q31149434 | Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease |
| Q35172679 | HCC development is associated to peripheral insulin resistance in a mouse model of NASH. |
| Q92715714 | HCMV-encoded IE2 promotes NAFLD progression by up-regulation of SREBP1c expression in UL122 genetically modified mice |
| Q44695666 | Heme oxygenase-1 gene promoter polymorphism and the risk of pediatric nonalcoholic fatty liver disease |
| Q33794679 | Hepatic Diacylglycerol-Associated Protein Kinase Cε Translocation Links Hepatic Steatosis to Hepatic Insulin Resistance in Humans |
| Q35809069 | Hepatic Steatosis as a Marker of Metabolic Dysfunction. |
| Q93234972 | Hepatic fatty acid synthesis and partitioning: the effect of metabolic and nutritional state |
| Q37296476 | Hepatic fatty acid trafficking: multiple forks in the road |
| Q37777696 | Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites |
| Q37333482 | Hepatic notch signaling correlates with insulin resistance and nonalcoholic fatty liver disease. |
| Q37257204 | High fat diet induced hepatic steatosis establishes a permissive microenvironment for colorectal metastases and promotes primary dysplasia in a murine model |
| Q51243542 | High-Fructose Intake Impairs the Hepatic Hypolipidemic Effects of a High-Fat Fish-Oil Diet in C57BL/6 Mice. |
| Q61818543 | Homeostasis of Glucose and Lipid in Non-Alcoholic Fatty Liver Disease |
| Q38765909 | Hypothalamic Insulin Resistance in Obesity: Effects on Glucose Homeostasis |
| Q37345871 | Impact of body weight, diet and lifestyle on nonalcoholic fatty liver disease. |
| Q53464592 | Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects. |
| Q47912507 | Impaired peripheral insulin sensitivity in non-obese Japanese patients with type 2 diabetes mellitus and fatty liver. |
| Q43294210 | Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis |
| Q46936115 | Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver |
| Q35871353 | Increased whole-body adiposity without a concomitant increase in liver fat is not associated with augmented metabolic dysfunction. |
| Q26827183 | Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease |
| Q33877805 | Independent tissue contributors to obesity-associated insulin resistance |
| Q47744258 | Influence of dietary macronutrients on liver fat accumulation and metabolism. |
| Q37386085 | Insulin resistance and steatosis in humans |
| Q51498367 | Insulin resistance and whole body energy homeostasis in obese adolescents with fatty liver disease. |
| Q26748687 | Insulin resistance in development and progression of nonalcoholic fatty liver disease |
| Q33873016 | Insulin resistance predicts mortality in nondiabetic individuals in the U.S. |
| Q36297331 | Insulin resistance: a metabolic pathway to chronic liver disease |
| Q39304941 | Insulin resistance: mechanism and implications for carcinogenesis and hepatocellular carcinoma in NASH. |
| Q34339449 | Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors. |
| Q35784740 | Intra-thoracic fat, cardiometabolic risk factors, and subclinical cardiovascular disease in healthy, recently menopausal women screened for the Kronos Early Estrogen Prevention Study (KEEPS). |
| Q41263470 | Is age a risk factor for liver disease and metabolic alterations in ataxia Telangiectasia patients? |
| Q51758740 | Ketone body production is differentially altered in steatosis and non-alcoholic steatohepatitis in obese humans. |
| Q38289344 | Lipidomic analysis reveals significant lipogenesis and accumulation of lipotoxic components in ob/ob mouse organs |
| Q37869703 | Lipids in the wrong place: visceral fat and nonalcoholic steatohepatitis |
| Q26866207 | Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches |
| Q84530245 | Liver fibrogenesis and metabolic factors |
| Q37068823 | Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects |
| Q40181436 | Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease |
| Q38365276 | Management and diagnosis of fatty liver disease |
| Q36577029 | Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance |
| Q90685522 | Mechanisms of Insulin Action and Insulin Resistance |
| Q51289305 | Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes. |
| Q46960296 | Metabolic conditions of fatty liver in non-diabetic obese women |
| Q35743894 | Metabolic consequences of ENPP1 overexpression in adipose tissue. |
| Q38949684 | Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges |
| Q35118774 | Metabolic inflexibility and insulin resistance in obese adolescents with non-alcoholic fatty liver disease |
| Q37590804 | Metformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. |
| Q51382232 | Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. |
| Q34750679 | MicroRNA-185 regulates expression of lipid metabolism genes and improves insulin sensitivity in mice with non-alcoholic fatty liver disease |
| Q35066721 | Microbiota and nonalcoholic steatohepatitis |
| Q26738646 | Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease |
| Q97549698 | Modifying nutritional substrates induces macrovesicular lipid droplet accumulation and metabolic alterations in a cellular model of hepatic steatosis |
| Q37437295 | Molecular mechanisms involved in NAFLD progression |
| Q89220189 | Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease |
| Q24622681 | Moro orange juice prevents fatty liver in mice |
| Q91902571 | Natural course of fatty liver in 36,195 South Korean adults |
| Q37437435 | New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). |
| Q36410552 | New treatments for nonalcoholic fatty liver disease |
| Q41706829 | Non-alcoholic Fatty Liver Disease in Lean Subjects: Characteristics and Implications |
| Q37002532 | Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease |
| Q26852019 | Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment |
| Q89624036 | Non-alcoholic fatty liver disease in lean individuals |
| Q37647216 | Non-alcoholic fatty liver disease may develop in individuals with normal body mass index |
| Q35543956 | Non-alcoholic fatty liver disease: The diagnosis and management |
| Q51366942 | Non-esterified fatty acid dynamics during oral glucose tolerance test in women with former gestational diabetes. |
| Q37742737 | Nonalcoholic Fatty Liver Disease and Associated Metabolic Risks of Hypertension in Type 2 Diabetes: A Cross-Sectional Community-Based Study |
| Q90360178 | Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective |
| Q63681503 | Nonalcoholic Fatty Liver Disease in The Rotterdam Study: About Muscle Mass, Sarcopenia, Fat Mass, and Fat Distribution |
| Q37678998 | Nonalcoholic Fatty Liver Disease: Clinical Features and Pathogenesis |
| Q33580031 | Nonalcoholic Fatty liver disease/non-alcoholic steatohepatitis in childhood: endocrine-metabolic "mal-programming". |
| Q37375539 | Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment |
| Q43136598 | Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis |
| Q33886930 | Nonalcoholic fatty liver disease and polycystic ovary syndrome |
| Q38430909 | Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms |
| Q26749290 | Nonalcoholic fatty liver disease as a multi-systemic disease |
| Q45852475 | Nonalcoholic fatty liver disease is associated with insulin resistance in a young Hispanic population |
| Q51550409 | Nonalcoholic fatty liver disease markers are associated with insulin resistance in type 1 diabetes. |
| Q84980641 | Nonalcoholic fatty liver disease: The hepatic trigger of the metabolic syndrome |
| Q37788538 | Nonalcoholic fatty liver disease: a challenge for pediatricians |
| Q57644643 | Nonalcoholic fatty liver disease: an independent risk factor for colorectal neoplasia |
| Q38859044 | Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes? |
| Q38290119 | Nonalcoholic steatohepatitis and insulin resistance in children |
| Q48040786 | Nonalcoholic steatohepatitis in nonobese patients: Not so different after all. |
| Q33644131 | Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: A post hoc analysis of a cohort study |
| Q35895832 | Nutrition and nonalcoholic Fatty liver disease: the significance of cholesterol |
| Q36617551 | Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications |
| Q33628222 | Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: Role of adipokines |
| Q28073381 | Obesity-Related Digestive Diseases and Their Pathophysiology |
| Q38053459 | Obstructive sleep apnoea and cardiovascular complications: perception versus knowledge |
| Q37285240 | PNPLA3 I148M polymorphism and progressive liver disease |
| Q36812508 | Pathogenesis and Prevention of Hepatic Steatosis |
| Q34449857 | Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease |
| Q92504940 | Pathogenesis of Insulin Resistance and Atherogenic Dyslipidemia in Nonalcoholic Fatty Liver Disease |
| Q35928495 | Pathogenesis of nonalcoholic steatohepatitis |
| Q28070011 | Pathophysiology of Non Alcoholic Fatty Liver Disease |
| Q37898424 | Pathophysiology of non-alcoholic steatohepatitis and basis for treatment |
| Q36199008 | Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism |
| Q46484710 | Perilipin-2 Deletion Impairs Hepatic Lipid Accumulation by Interfering with Sterol Regulatory Element-binding Protein (SREBP) Activation and Altering the Hepatic Lipidome |
| Q53813254 | Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. |
| Q36619149 | Peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic Fatty liver disease: any role in disease susceptibility? |
| Q34180137 | Plasma metabolomic profile in nonalcoholic fatty liver disease. |
| Q41059980 | Practical management of the increasing burden of non-alcoholic fatty liver disease |
| Q51054709 | Prevalence of Insulin Resistance in Subjects with Nonalcoholic Fatty Liver Disease and Its Predictors in a Chinese Population. |
| Q37198732 | Prevalence of non-alcoholic fatty liver disease in children and relationship to metabolic syndrome, insulin resistance, and waist circumference |
| Q51488549 | Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. |
| Q51322897 | Preventing non-alcoholic fatty liver disease through Lactobacillus johnsonii BS15 by attenuating inflammation and mitochondrial injury and improving gut environment in obese mice. |
| Q38408904 | Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease |
| Q24656684 | Redox mechanisms in hepatic chronic wound healing and fibrogenesis |
| Q46784370 | Reduced intrahepatic fat content is associated with increased whole-body lipid oxidation in patients with type 1 diabetes |
| Q36316335 | Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering? |
| Q36205001 | Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up st |
| Q100635338 | Relative fat mass at baseline and its early change may be a predictor of incident nonalcoholic fatty liver disease |
| Q43815610 | Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging |
| Q37056681 | Risk factors of chronic hepatitis in antiretroviral-treated HIV infection, without hepatitis B or C viral infection |
| Q37921905 | Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus |
| Q38209324 | Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools |
| Q91611223 | Role of ketone signaling in the hepatic response to fasting |
| Q37345849 | Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes. |
| Q90067935 | Sarcopenia Is Independently Associated with the Degree of Liver Fibrosis in Patients with Type 2 Diabetes Mellitus |
| Q41191108 | Sex-influenced association of non-alcoholic fatty liver disease with colorectal adenomatous and hyperplastic polyps |
| Q33516103 | Simple modeling allows prediction of steady-state glucose disposal rate from early data in hyperinsulinemic glucose clamps. |
| Q42456523 | Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. |
| Q58149661 | Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? |
| Q80002035 | Statins and hepatic steatosis: perspectives from the Dallas Heart Study |
| Q33907632 | Steatosis and steatohepatitis: complex disorders |
| Q47551195 | Steatosis in South African women: How much and why? |
| Q38165140 | Steatosis in the liver. |
| Q53640589 | Strong and persistent effect on liver fat with a Paleolithic diet during a two-year intervention. |
| Q36373567 | The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease |
| Q58147152 | The Finnish Diabetes Risk Score (FINDRISC) as a screening tool for hepatic steatosis |
| Q34382081 | The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls |
| Q58798256 | The PI3K/AKT pathway in obesity and type 2 diabetes |
| Q37110166 | The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter. |
| Q36329899 | The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis |
| Q34026359 | The in utero programming effect of increased maternal androgens and a direct fetal intervention on liver and metabolic function in adult sheep |
| Q52873745 | The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. |
| Q49391011 | The relationship of alanine aminotransferase to metabolic syndrome in a Korean population. |
| Q53071821 | The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease. |
| Q38660769 | The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development--a potential therapeutic target? |
| Q93350798 | The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis |
| Q39837126 | The severity of non-alcoholic fatty liver disease correlates with high sensitivity C-reactive protein value and is independently associated with increased cardiovascular risk in healthy population |
| Q55168115 | The therapeutic effects of bee venom on some metabolic and antioxidant parameters associated with HFD-induced non-alcoholic fatty liver in rats. |
| Q46896417 | Tissue specificity of insulin resistance in humans: fat in the liver rather than muscle is associated with features of the metabolic syndrome |
| Q26775632 | Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss |
| Q88609413 | Triggering and resolution of inflammation in NASH |
| Q26752583 | Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight |
| Q40153908 | Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study |
| Q33610786 | Viewpoints on the way to a consensus session: where does insulin resistance start? The liver |
| Q33610688 | Viewpoints on the way to the consensus session: where does insulin resistance start? The adipose tissue |
| Q35935452 | White Pitaya (Hylocereus undatus) Juice Attenuates Insulin Resistance and Hepatic Steatosis in Diet-Induced Obese Mice |
| Q37856880 | Why does NAFLD predict type 2 diabetes? |
| Q33815927 | miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice |
Search more.